6533b852fe1ef96bd12aa4cc
RESEARCH PRODUCT
Facing the dawn of immunotherapy for hepatocellular carcinoma.
Martin F. SprinzlPeter R. Gallesubject
Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusAntineoplastic Agentsmedicine.disease_causeAntibodies Monoclonal HumanizedGastroenterologyAntiviral AgentsInternal medicinemedicineHumansCTLA-4 AntigenHepatitisHepatologybusiness.industryLiver NeoplasmsAntibodies MonoclonalHepatitis CHepatitis C Chronicmedicine.diseaseRashHepatocellular carcinomaImmunologyFemaleLiver functionmedicine.symptombusinessTremelimumabmedicine.drugdescription
In this study, administration of tremelimumab was accompanied by a tolerable toxicity profile, most frequently including skin rash (65%), fatigue (55%), and anorexia (50%). During the initial course of tremilimumab, a transient increase of serum transaminase activity was observed. Hepatotoxicity did not impair liver function, even in the context of Child-Pugh B cirrhosis and hepatitis C. Therapy was stopped in 3 patients before tumor response evaluation was completed due to tremilimumab-related diarrhea or clinical deterioration, which was not associated with the treatment regimen. The relevance of this study is strengthened by the inclusion of HCC patients, showing hepatitis C associated cirrhosis, which represents a typical clinical scenario. However, the safety profile outlined above might not apply to HCC in association with other liver diseases. Particularly chronic hepatitis B, which shows higher liver failure rates due to inflammatory flares compared to hepatitis C, might respond differently to CTLA-4 blockage.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-07-01 | Journal of hepatology |